显示样式:     当前分类: 医药    当前期刊: Nature Reviews Rheumatology    加入关注    导出
我的关注
我的收藏
您暂时未登录!
登录
  • Inflammation: Cytokines alter inflammatory responses via chromatin changes
    Nat. Rev. Rheumatol. (IF 12.188) Pub Date : 
    Sarah Onuora

    Inflammation: Cytokines alter inflammatory responses via chromatin changes Nature Reviews Rheumatology, Published online: 22 September 2017; doi:10.1038/nrrheum.2017.154

    更新日期:2017-09-22
  • Synovial tissue research: a state-of-the-art review
    Nat. Rev. Rheumatol. (IF 12.188) Pub Date : 
    Carl Orr, Elsa Vieira-Sousa, David L. Boyle, Maya H. Buch, Christopher D. Buckley, Juan D. Cañete, Anca I. Catrina, Ernest H. S. Choy, Paul Emery, Ursula Fearon, Andrew Filer, Danielle Gerlag, Frances Humby, John D. Isaacs, Søren A. Just, Bernard R. Lauwerys, Benoit Le Goff, Antonio Manzo, Trudy McGarry, Iain B. McInnes, Aurélie Najm, Constantino Pitzalis, Arthur Pratt, Malcolm Smith, Paul P. Tak, Rogier Thurlings, João E. Fonseca, Douglas J. Veale

    Synovial tissue research: a state-of-the-art review Nature Reviews Rheumatology, Published online: 22 September 2017; doi:10.1038/nrrheum.2017.161

    更新日期:2017-09-22
  • Inflammation: Cytokines alter inflammatory responses via chromatin changes
    Nat. Rev. Rheumatol. (IF 12.188) Pub Date : 
    Sarah Onuora

    Inflammation: Cytokines alter inflammatory responses via chromatin changes Nature Reviews Rheumatology, Published online: 22 September 2017; doi:10.1038/nrrheum.2017.154

    更新日期:2017-09-22
  • Synovial tissue research: a state-of-the-art review
    Nat. Rev. Rheumatol. (IF 12.188) Pub Date : 
    Carl Orr, Elsa Vieira-Sousa, David L. Boyle, Maya H. Buch, Christopher D. Buckley, Juan D. Cañete, Anca I. Catrina, Ernest H. S. Choy, Paul Emery, Ursula Fearon, Andrew Filer, Danielle Gerlag, Frances Humby, John D. Isaacs, Søren A. Just, Bernard R. Lauwerys, Benoit Le Goff, Antonio Manzo, Trudy McGarry, Iain B. McInnes, Aurélie Najm, Constantino Pitzalis, Arthur Pratt, Malcolm Smith, Paul P. Tak, Rogier Thurlings, João E. Fonseca, Douglas J. Veale

    Synovial tissue research: a state-of-the-art review Nature Reviews Rheumatology, Published online: 22 September 2017; doi:10.1038/nrrheum.2017.161

    更新日期:2017-09-22
  • Therapy: Are you managing osteoarthritis appropriately?
    Nat. Rev. Rheumatol. (IF 12.188) Pub Date : 
    David J. Hunter, Jocelyn L. Bowden

    Therapy: Are you managing osteoarthritis appropriately?Nature Reviews Rheumatology, Published online: 21 September 2017; doi:10.1038/nrrheum.2017.160For patients with osteoarthritis, the current palliative approach of analgesic prescription followed by joint replacement is often inappropriate. Instead, care should be tailored to the needs of individuals and targeted towards the central complaints of pain and functional limitation. So why are we still getting it wrong?

    更新日期:2017-09-21
  • Therapy: Are you managing osteoarthritis appropriately?
    Nat. Rev. Rheumatol. (IF 12.188) Pub Date : 
    David J. Hunter, Jocelyn L. Bowden

    Therapy: Are you managing osteoarthritis appropriately?Nature Reviews Rheumatology, Published online: 21 September 2017; doi:10.1038/nrrheum.2017.160For patients with osteoarthritis, the current palliative approach of analgesic prescription followed by joint replacement is often inappropriate. Instead, care should be tailored to the needs of individuals and targeted towards the central complaints of pain and functional limitation. So why are we still getting it wrong?

    更新日期:2017-09-21
  • Position paper: Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis
    Nat. Rev. Rheumatol. (IF 12.188) Pub Date : 
    Xavier Bossuyt, Jan-Willem Cohen Tervaert, Yoshihiro Arimura, Daniel Blockmans, Luis Felipe Flores-Suárez, Loïc Guillevin, Bernhard Hellmich, David Jayne, J. Charles Jennette, Cees G. M. Kallenberg, Sergey Moiseev, Pavel Novikov, Antonella Radice, Judith Anne Savige, Renato Alberto Sinico, Ulrich Specks, Pieter van Paassen, Ming-hui Zhao, Niels Rasmussen, Jan Damoiseaux, Elena Csernok

    Position paper: Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis Nature Reviews Rheumatology, Published online: 14 September 2017; doi:10.1038/nrrheum.2017.140 In this Consensus Statement, a group of experts propose that high-quality immunoassays, rather than indirect immunofluorescence, should be used as the primary screening method for detecting anti-neutrophil cytoplasmic antibodies when diagnosing patients with suspected granulomatosis with polyangiitis or microscopic polyangiitis.

    更新日期:2017-09-15
  • Giant cell arteritis and polymyalgia rheumatica: current challenges and opportunities
    Nat. Rev. Rheumatol. (IF 12.188) Pub Date : 
    Christian Dejaco, Elisabeth Brouwer, Justin C. Mason, Frank Buttgereit, Eric L. Matteson, Bhaskar Dasgupta

    The fields of giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) have advanced rapidly, resulting in a new understanding of these diseases. Fast-track strategies and improved awareness programmes that prevent irreversible sight loss through early diagnosis and treatment are a notable advance. Ultrasonography and other imaging techniques have been introduced into routine clinical practice and there have been promising reports on the efficacy of biologic agents, particularly IL-6 antagonists such as tocilizumab, in treating these conditions. Along with these developments, which should improve outcomes in patients with GCA and PMR, new questions and unmet needs have emerged; future research should address which pathogenetic mechanisms contribute to the different phases and clinical phenotypes of GCA, what role imaging has in the early diagnosis and monitoring of GCA and PMR, and in which patients and phases of these diseases novel biologic drugs should be used. This article discusses the implications of recent developments in our understanding of GCA and PMR, as well as the unmet needs concerning epidemiology, pathogenesis, imaging and treatment of these diseases.

    更新日期:2017-09-15
  • Differential antibody glycosylation in autoimmunity: sweet biomarker or modulator of disease activity?
    Nat. Rev. Rheumatol. (IF 12.188) Pub Date : 
    Michaela Seeling, Christin Brückner, Falk Nimmerjahn

    A loss of humoral tolerance is a hallmark of many autoimmune diseases and the detection of self-reactive antibodies (autoantibodies) of the immunoglobulin G (IgG) isotype is widely used as a biomarker and diagnostic tool. However, autoantibodies might also be present in individuals without autoimmune disease, thus limiting their usefulness as a sole indicator of disease development. Moreover, while clear evidence exists of the pathogenic effects of autoantibodies in mouse model systems, the contribution of autoantibodies to the pathology of many autoimmune diseases has yet to be established. In this Review, the authors discuss the changes in total serum IgG and autoantibody glycosylation that occur during autoimmune disease and how these changes might help to predict disease development in the future. Furthermore, current knowledge of the signals regulating antibody glycosylation and how individual antibody glycoforms could be used to optimize current treatment approaches will be discussed.

    更新日期:2017-09-15
  • Bone: Targeting old cells to protect old bones
    Nat. Rev. Rheumatol. (IF 12.188) Pub Date : 
    Joanna Collison

    Bone: Targeting old cells to protect old bones Nature Reviews Rheumatology, Published online: 14 September 2017; doi:10.1038/nrrheum.2017.152

    更新日期:2017-09-15
  • Risk factors: Oral contraceptive use linked to lower risk of RA
    Nat. Rev. Rheumatol. (IF 12.188) Pub Date : 
    Sarah Onuora

    Risk factors: Oral contraceptive use linked to lower risk of RA Nature Reviews Rheumatology, Published online: 14 September 2017; doi:10.1038/nrrheum.2017.156

    更新日期:2017-09-15
  • Infection: Infection risk after switching biologics
    Nat. Rev. Rheumatol. (IF 12.188) Pub Date : 
    Sarah Onuora

    Infection: Infection risk after switching biologics Nature Reviews Rheumatology, Published online: 14 September 2017; doi:10.1038/nrrheum.2017.158

    更新日期:2017-09-15
  • New insights into the epigenetics of inflammatory rheumatic diseases
    Nat. Rev. Rheumatol. (IF 12.188) Pub Date : 
    Esteban Ballestar, Tianlu Li

    Over the past decade, awareness of the importance of epigenetic alterations in the pathogenesis of rheumatic diseases has grown in parallel with a general recognition of the fundamental role of epigenetics in the regulation of gene expression. Large-scale efforts to generate genome-wide maps of epigenetic modifications in different cell types, as well as in physiological and pathological contexts, illustrate the increasing recognition of the relevance of epigenetics. To date, although several reports have demonstrated the occurrence of epigenetic alterations in a wide range of inflammatory rheumatic conditions, epigenomic information is rarely used in a clinical setting. By contrast, several epigenetic biomarkers and treatments are currently in use for personalized therapies in patients with cancer. This Review highlights advances from the past 5 years in the field of epigenetics and their application to inflammatory rheumatic diseases, delineating the future lines of development for a rational use of epigenetic information in clinical settings and in personalized medicine. These advances include the identification of epipolymorphisms associated with clinical outcomes, DNA methylation as a contributor to disease susceptibility in rheumatic conditions, the discovery of novel epigenetic mechanisms that modulate disease susceptibility and the development of new epigenetic therapies.

    更新日期:2017-09-15
  • Rheumatoid arthritis: Reducing the risk of herpes zoster
    Nat. Rev. Rheumatol. (IF 12.188) Pub Date : 
    Jessica McHugh

    Rheumatoid arthritis: Reducing the risk of herpes zoster Nature Reviews Rheumatology, Published online: 14 September 2017; doi:10.1038/nrrheum.2017.153

    更新日期:2017-09-15
  • Position paper: Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis
    Nat. Rev. Rheumatol. (IF 12.188) Pub Date : 2017-09-14
    Xavier Bossuyt, Jan-Willem Cohen Tervaert, Yoshihiro Arimura, Daniel Blockmans, Luis Felipe Flores-Suárez, Loïc Guillevin, Bernhard Hellmich, David Jayne, J. Charles Jennette, Cees G. M. Kallenberg, Sergey Moiseev, Pavel Novikov, Antonella Radice, Judith Anne Savige, Renato Alberto Sinico, Ulrich Specks, Pieter van Paassen, Ming-hui Zhao, Niels Rasmussen, Jan Damoiseaux, Elena Csernok

    Position paper: Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis Nature Reviews Rheumatology, Published online: 14 September 2017; doi:10.1038/nrrheum.2017.140 In this Consensus Statement, a group of experts propose that high-quality immunoassays, rather than indirect immunofluorescence, should be used as the primary screening method for detecting anti-neutrophil cytoplasmic antibodies when diagnosing patients with suspected granulomatosis with polyangiitis or microscopic polyangiitis.

    更新日期:2017-09-15
  • Giant cell arteritis and polymyalgia rheumatica: current challenges and opportunities
    Nat. Rev. Rheumatol. (IF 12.188) Pub Date : 2017-09-14
    Christian Dejaco, Elisabeth Brouwer, Justin C. Mason, Frank Buttgereit, Eric L. Matteson, Bhaskar Dasgupta

    The fields of giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) have advanced rapidly, resulting in a new understanding of these diseases. Fast-track strategies and improved awareness programmes that prevent irreversible sight loss through early diagnosis and treatment are a notable advance. Ultrasonography and other imaging techniques have been introduced into routine clinical practice and there have been promising reports on the efficacy of biologic agents, particularly IL-6 antagonists such as tocilizumab, in treating these conditions. Along with these developments, which should improve outcomes in patients with GCA and PMR, new questions and unmet needs have emerged; future research should address which pathogenetic mechanisms contribute to the different phases and clinical phenotypes of GCA, what role imaging has in the early diagnosis and monitoring of GCA and PMR, and in which patients and phases of these diseases novel biologic drugs should be used. This article discusses the implications of recent developments in our understanding of GCA and PMR, as well as the unmet needs concerning epidemiology, pathogenesis, imaging and treatment of these diseases.

    更新日期:2017-09-15
  • Differential antibody glycosylation in autoimmunity: sweet biomarker or modulator of disease activity?
    Nat. Rev. Rheumatol. (IF 12.188) Pub Date : 2017-09-14
    Michaela Seeling, Christin Brückner, Falk Nimmerjahn

    A loss of humoral tolerance is a hallmark of many autoimmune diseases and the detection of self-reactive antibodies (autoantibodies) of the immunoglobulin G (IgG) isotype is widely used as a biomarker and diagnostic tool. However, autoantibodies might also be present in individuals without autoimmune disease, thus limiting their usefulness as a sole indicator of disease development. Moreover, while clear evidence exists of the pathogenic effects of autoantibodies in mouse model systems, the contribution of autoantibodies to the pathology of many autoimmune diseases has yet to be established. In this Review, the authors discuss the changes in total serum IgG and autoantibody glycosylation that occur during autoimmune disease and how these changes might help to predict disease development in the future. Furthermore, current knowledge of the signals regulating antibody glycosylation and how individual antibody glycoforms could be used to optimize current treatment approaches will be discussed.

    更新日期:2017-09-15
  • Bone: Targeting old cells to protect old bones
    Nat. Rev. Rheumatol. (IF 12.188) Pub Date : 
    Joanna Collison

    Bone: Targeting old cells to protect old bones Nature Reviews Rheumatology, Published online: 14 September 2017; doi:10.1038/nrrheum.2017.152

    更新日期:2017-09-15
  • Risk factors: Oral contraceptive use linked to lower risk of RA
    Nat. Rev. Rheumatol. (IF 12.188) Pub Date : 
    Sarah Onuora

    Risk factors: Oral contraceptive use linked to lower risk of RA Nature Reviews Rheumatology, Published online: 14 September 2017; doi:10.1038/nrrheum.2017.156

    更新日期:2017-09-15
  • Infection: Infection risk after switching biologics
    Nat. Rev. Rheumatol. (IF 12.188) Pub Date : 
    Sarah Onuora

    Infection: Infection risk after switching biologics Nature Reviews Rheumatology, Published online: 14 September 2017; doi:10.1038/nrrheum.2017.158

    更新日期:2017-09-15
  • New insights into the epigenetics of inflammatory rheumatic diseases
    Nat. Rev. Rheumatol. (IF 12.188) Pub Date : 2017-09-14
    Esteban Ballestar, Tianlu Li

    Over the past decade, awareness of the importance of epigenetic alterations in the pathogenesis of rheumatic diseases has grown in parallel with a general recognition of the fundamental role of epigenetics in the regulation of gene expression. Large-scale efforts to generate genome-wide maps of epigenetic modifications in different cell types, as well as in physiological and pathological contexts, illustrate the increasing recognition of the relevance of epigenetics. To date, although several reports have demonstrated the occurrence of epigenetic alterations in a wide range of inflammatory rheumatic conditions, epigenomic information is rarely used in a clinical setting. By contrast, several epigenetic biomarkers and treatments are currently in use for personalized therapies in patients with cancer. This Review highlights advances from the past 5 years in the field of epigenetics and their application to inflammatory rheumatic diseases, delineating the future lines of development for a rational use of epigenetic information in clinical settings and in personalized medicine. These advances include the identification of epipolymorphisms associated with clinical outcomes, DNA methylation as a contributor to disease susceptibility in rheumatic conditions, the discovery of novel epigenetic mechanisms that modulate disease susceptibility and the development of new epigenetic therapies.

    更新日期:2017-09-15
  • Rheumatoid arthritis: Reducing the risk of herpes zoster
    Nat. Rev. Rheumatol. (IF 12.188) Pub Date : 
    Jessica McHugh

    Rheumatoid arthritis: Reducing the risk of herpes zoster Nature Reviews Rheumatology, Published online: 14 September 2017; doi:10.1038/nrrheum.2017.153

    更新日期:2017-09-15
  • Vasculitis syndromes: Tocilizumab — a new frontier for GCA therapy
    Nat. Rev. Rheumatol. (IF 12.188) Pub Date : 
    Matthew J. Koster, Kenneth J. Warrington

    Vasculitis syndromes: Tocilizumab — a new frontier for GCA therapyNature Reviews Rheumatology, Published online: 7 September 2017; doi:10.1038/nrrheum.2017.150An unmet need exists for effective glucocorticoid-sparing agents for the treatment of giant cell arteritis (GCA). Tocilizumab, the first intervention to demonstrate substantial therapeutic benefits for patients with newly diagnosed or relapsing GCA, is changing the landscape of treatment and ushering in a new era of biologic therapy.

    更新日期:2017-09-12
  • Systemic lupus erythematosus: OX40L-expressing B cells promote SLE
    Nat. Rev. Rheumatol. (IF 12.188) Pub Date : 
    Jessica McHugh

    Systemic lupus erythematosus: OX40L-expressing B cells promote SLENature Reviews Rheumatology, Published online: 7 September 2017; doi:10.1038/nrrheum.2017.151

    更新日期:2017-09-12
  • Rheumatoid arthritis: Cell cycle stalling linked to arthritis
    Nat. Rev. Rheumatol. (IF 12.188) Pub Date : 
    Joanna Collison

    Rheumatoid arthritis: Cell cycle stalling linked to arthritisNature Reviews Rheumatology, Published online: 31 August 2017; doi:10.1038/nrrheum.2017.148

    更新日期:2017-09-12
  • Bone: Towards a better management of glucocorticoid-induced osteoporosis?
    Nat. Rev. Rheumatol. (IF 12.188) Pub Date : 
    René Rizzoli

    Bone: Towards a better management of glucocorticoid-induced osteoporosis?Nature Reviews Rheumatology, Published online: 31 August 2017; doi:10.1038/nrrheum.2017.141A new publication by the ACR provides clear recommendations for the prevention and treatment of osteoporosis in patients being treated with glucocorticoids, but will they improve the historically inadequate management of this patient population?

    更新日期:2017-09-12
  • Rheumatoid arthritis: Remission — keeping the patient experience front and centre
    Nat. Rev. Rheumatol. (IF 12.188) Pub Date : 
    Lilian H. D. van Tuyl, Maarten Boers

    Rheumatoid arthritis: Remission — keeping the patient experience front and centreNature Reviews Rheumatology, Published online: 31 August 2017; doi:10.1038/nrrheum.2017.139Interpreting existing patient-reported outcome measures for the experience of remission by patients with rheumatoid arthritis is not straightforward. The challenge is to find a better, more accurate measure.

    更新日期:2017-09-12
  • Rheumatoid arthritis: Characterization of the infrapatellar fat pad
    Nat. Rev. Rheumatol. (IF 12.188) Pub Date : 
    Liesbet Lieben

    Rheumatoid arthritis: Characterization of the infrapatellar fat padNature Reviews Rheumatology, Published online: 31 August 2017; doi:10.1038/nrrheum.2017.145

    更新日期:2017-09-12
  • Immunology: Balancing immunoreceptor signalling
    Nat. Rev. Rheumatol. (IF 12.188) Pub Date : 
    Jessica McHugh

    Immunology: Balancing immunoreceptor signallingNature Reviews Rheumatology, Published online: 31 August 2017; doi:10.1038/nrrheum.2017.149

    更新日期:2017-09-12
  • Functional autoantibodies targeting G protein-coupled receptors in rheumatic diseases
    Nat. Rev. Rheumatol. (IF 12.188) Pub Date : 
    Otavio Cabral-Marques, Gabriela Riemekasten

    G protein-coupled receptors (GPCRs) comprise the largest and most diverse family of integral membrane proteins that participate in different physiological processes such as the regulation of the nervous and immune systems. Besides the endogenous ligands of GPCRs, functional autoantibodies are also able to bind GPCRs to trigger or block intracellular signalling pathways, resulting in agonistic or antagonistic effects, respectively. In this Review, the effects of functional GPCR-targeting autoantibodies on the pathogenesis of autoimmune diseases, including rheumatic diseases, are discussed. Autoantibodies targeting β1 and β2 adrenergic receptors, which are expressed by cardiac and airway smooth muscle cells, respectively, have an important role in the development of asthma and cardiovascular diseases. In addition, high levels of autoantibodies against the muscarinic acetylcholine receptor M3 as well as those targeting endothelin receptor type A and type 1 angiotensin II receptor have several implications in the pathogenesis of rheumatic diseases such as Sjögren syndrome and systemic sclerosis. Expanding the knowledge of the pathophysiological roles of autoantibodies against GPCRs will shed light on the biology of these receptors and open avenues for new therapeutic approaches.

    更新日期:2017-09-12
  • Vasculitis syndromes: Tocilizumab — a new frontier for GCA therapy
    Nat. Rev. Rheumatol. (IF 12.188) Pub Date : 2017-09-07
    Matthew J. Koster, Kenneth J. Warrington

    Vasculitis syndromes: Tocilizumab — a new frontier for GCA therapyNature Reviews Rheumatology, Published online: 7 September 2017; doi:10.1038/nrrheum.2017.150An unmet need exists for effective glucocorticoid-sparing agents for the treatment of giant cell arteritis (GCA). Tocilizumab, the first intervention to demonstrate substantial therapeutic benefits for patients with newly diagnosed or relapsing GCA, is changing the landscape of treatment and ushering in a new era of biologic therapy.

    更新日期:2017-09-12
  • Systemic lupus erythematosus: OX40L-expressing B cells promote SLE
    Nat. Rev. Rheumatol. (IF 12.188) Pub Date : 
    Jessica McHugh

    Systemic lupus erythematosus: OX40L-expressing B cells promote SLENature Reviews Rheumatology, Published online: 7 September 2017; doi:10.1038/nrrheum.2017.151

    更新日期:2017-09-12
  • Rheumatoid arthritis: Cell cycle stalling linked to arthritis
    Nat. Rev. Rheumatol. (IF 12.188) Pub Date : 
    Joanna Collison

    Rheumatoid arthritis: Cell cycle stalling linked to arthritisNature Reviews Rheumatology, Published online: 31 August 2017; doi:10.1038/nrrheum.2017.148

    更新日期:2017-09-12
  • Bone: Towards a better management of glucocorticoid-induced osteoporosis?
    Nat. Rev. Rheumatol. (IF 12.188) Pub Date : 2017-08-31
    René Rizzoli

    Bone: Towards a better management of glucocorticoid-induced osteoporosis?Nature Reviews Rheumatology, Published online: 31 August 2017; doi:10.1038/nrrheum.2017.141A new publication by the ACR provides clear recommendations for the prevention and treatment of osteoporosis in patients being treated with glucocorticoids, but will they improve the historically inadequate management of this patient population?

    更新日期:2017-09-12
  • Rheumatoid arthritis: Remission — keeping the patient experience front and centre
    Nat. Rev. Rheumatol. (IF 12.188) Pub Date : 2017-08-31
    Lilian H. D. van Tuyl, Maarten Boers

    Rheumatoid arthritis: Remission — keeping the patient experience front and centreNature Reviews Rheumatology, Published online: 31 August 2017; doi:10.1038/nrrheum.2017.139Interpreting existing patient-reported outcome measures for the experience of remission by patients with rheumatoid arthritis is not straightforward. The challenge is to find a better, more accurate measure.

    更新日期:2017-09-12
  • Rheumatoid arthritis: Characterization of the infrapatellar fat pad
    Nat. Rev. Rheumatol. (IF 12.188) Pub Date : 
    Liesbet Lieben

    Rheumatoid arthritis: Characterization of the infrapatellar fat padNature Reviews Rheumatology, Published online: 31 August 2017; doi:10.1038/nrrheum.2017.145

    更新日期:2017-09-12
  • Immunology: Balancing immunoreceptor signalling
    Nat. Rev. Rheumatol. (IF 12.188) Pub Date : 
    Jessica McHugh

    Immunology: Balancing immunoreceptor signallingNature Reviews Rheumatology, Published online: 31 August 2017; doi:10.1038/nrrheum.2017.149

    更新日期:2017-09-12
  • Functional autoantibodies targeting G protein-coupled receptors in rheumatic diseases
    Nat. Rev. Rheumatol. (IF 12.188) Pub Date : 2017-08-31
    Otavio Cabral-Marques, Gabriela Riemekasten

    Functional autoantibodies targeting G protein-coupled receptors in rheumatic diseasesNature Reviews Rheumatology, Published online: 31 August 2017; doi:10.1038/nrrheum.2017.134Autoantibodies are known to regulate the function of G protein-coupled receptors (GPCRs), but the involvement of such functional autoantibodies in autoimmune disorders is not fully understood. In this Review, the author discuss evidence showing agonistic and antagonistic effects of anti-GPCR functional autoantibodies in the pathogenesis of different rheumatic diseases.

    更新日期:2017-09-12
  • Rheumatoid arthritis: DMARD de-escalation — let the patient guide you
    Nat. Rev. Rheumatol. (IF 12.188) Pub Date : 2017-08-10
    Yoshiya Tanaka

    The DRESS study has shown that safety and efficacy were maintained for up to 3 years upon disease activity-guided dose reduction of TNF inhibitors. However, which patients are ideally suited for de-escalation remains to be investigated.

    更新日期:2017-09-06
  • Osteoarthritis: Chondroitin sulfate — CONCEPT clear, uncertainties unchanged
    Nat. Rev. Rheumatol. (IF 12.188) Pub Date : 2017-08-17
    Gabriel Herrero-Beaumont, Raquel Largo

    The newly published findings from the Chondroitin Versus Celecoxib Versus Placebo Trial (CONCEPT) underscore the complexity of performing clinical trials in the field of knee osteoarthritis. But do the results of CONCEPT merit the consideration of chondroitin sulfate as a first-line therapy?

    更新日期:2017-09-06
  • Spondyloarthropathies: Ruminococcus on the horizon in arthritic disease
    Nat. Rev. Rheumatol. (IF 12.188) Pub Date : 2017-08-17
    Lars Vereecke, Dirk Elewaut

    Increasing evidence points to a mechanistic link between gut and joint pathology as the gut contains the largest number of immune cells of any tissue and trillions of commensals that contribute to immune development and homeostasis. New research is putting the role of Ruminococcus gnavus in arthritic disease in the spotlight.

    更新日期:2017-09-06
  • The case for periodontitis in the pathogenesis of rheumatoid arthritis
    Nat. Rev. Rheumatol. (IF 12.188) Pub Date : 2017-08-24
    Jan Potempa, Piotr Mydel, Joanna Koziel

    Rheumatoid arthritis (RA), an autoimmune disease that affects ~1% of the human population, is driven by autoantibodies that target modified self-epitopes, whereas ~11% of the global adult population are affected by severe chronic periodontitis, a disease in which the commensal microflora on the tooth surface is replaced by a dysbiotic consortium of bacteria that promote the chronic inflammatory destruction of periodontal tissue. Despite differences in aetiology, RA and periodontitis are similar in terms of pathogenesis; both diseases involve chronic inflammation fuelled by pro-inflammatory cytokines, connective tissue breakdown and bone erosion. The two diseases also share risk factors such as smoking and ageing, and have strong epidemiological, serological and clinical associations. In light of the ground-breaking discovery that Porphyromonas gingivalis, a pivotal periodontal pathogen, is the only human pathogen known to express peptidylarginine deiminase, an enzyme that generates citrullinated epitopes that are recognized by anti-citrullinated protein antibodies, a new paradigm is emerging. In this Review, the clinical and experimental evidence supporting this paradigm is discussed and the potential mechanisms involved in linking periodontitis to RA are presented.

    更新日期:2017-09-06
  • Inflammation: Resolving — rather than suppressing — inflammation in RA might be the answer
    Nat. Rev. Rheumatol. (IF 12.188) Pub Date : 2017-07-27
    Mina Razzak

    New research published in Nature Medicine has revealed that IL-9, produced by group 2 innate lymphoid cells (ILC2s), might be a regulatory factor that contributes to the resolution of damage in chronic inflammatory diseases such as rheumatoid arthritis (RA). These findings support the notion

    更新日期:2017-09-06
  • Rheumatoid arthritis: ACPA-specific synovial immunophenotypes
    Nat. Rev. Rheumatol. (IF 12.188) Pub Date : 2017-08-10
    Dario Ummarino

    In a prospective study of 123 patients with rheumatoid arthritis, synovial tissue from anti-citrullinated protein antibody (ACPA)-positive patients had higher numbers of CD19+ B cells as well as CD3+ and CD8+ T cells compared with tissue from ACPA-negative patients.

    更新日期:2017-09-06
  • Osteoporosis: Romosozumab versus teriparatide
    Nat. Rev. Rheumatol. (IF 12.188) Pub Date : 2017-08-10
    Dario Ummarino

    The effect of two bone-forming agents — the anti-sclerostin antibody romosozumab and the recombinant PTH teriparatide — were compared in an open-label, randomized phase III study involving 436 women with postmenopausal osteoporosis who had been receiving bisphosphonate therapy. Change from baseline in total hip areal

    更新日期:2017-09-06
  • Vasculitis syndromes: Notch one up for the endothelium
    Nat. Rev. Rheumatol. (IF 12.188) Pub Date : 2017-08-10
    Joanna Collison

    The vasa vasorum is a microvascular network that lies within the walls of large arteries and, in healthy individuals, protects the arteries from inflammation by controlling access to the adventitia. In vasculitis syndromes, such as giant cell arteritis (GCA), this protective system is breached. A

    更新日期:2017-09-06
  • Experimental arthritis: PUMA reduces inflammation in arthritic joints
    Nat. Rev. Rheumatol. (IF 12.188) Pub Date : 2017-08-10
    Dario Ummarino

    Gene therapy with PUMA (also known as BBC3), a pro-apoptotic gene encoding BCL2-binding component 3, has been hampered by poor gene-delivery efficiency. A new study shows that conjugating human adenovirus type 5 (HAdV5) to a baculovirus vector expressing CAR on its envelope (BV

    更新日期:2017-09-06
  • Osteoarthritis: Matrix turnover linked to dietary weight loss
    Nat. Rev. Rheumatol. (IF 12.188) Pub Date : 2017-08-10
    Dario Ummarino

    A post hoc analysis of the IDEA trial, a prospective, randomized trial involving overweight and obese patients aged ≥55 years with osteoarthritis, reveals that serum markers of matrix metalloproteinase-mediated type I collagen degradation are lower among patients undergoing diet-induced weight loss, with or without

    更新日期:2017-09-06
  • Spondyloarthritis: Reinforcing 'treat to target' for SpA
    Nat. Rev. Rheumatol. (IF 12.188) Pub Date : 2017-08-03
    Sarah Onuora

    An international task force has presented updated recommendations for treating spondyloarthritis (SpA) to target. The 2017 recommendations, published in Annals of the Rheumatic Diseases, reflect new evidence and insights gained in the years since treat-to-target recommendations for SpA were first put forward in 2012.

    更新日期:2017-09-06
  • Systemic lupus erythematosus: A repertoire for disaster
    Nat. Rev. Rheumatol. (IF 12.188) Pub Date : 2017-07-20
    Jessica McHugh

    Loss of PR domain zinc finger protein 1 (PRDM1, also known as BLIMP1) in dendritic cells (DCs) results in an altered T follicular helper (TFH) cell repertoire, thereby potentially contributing to the development of systemic lupus erythematosus (SLE), according to new findings published

    更新日期:2017-09-06
  • Rheumatoid arthritis: JAK-ing up inadequate RA therapy
    Nat. Rev. Rheumatol. (IF 12.188) Pub Date : 2017-07-06
    Sarah Onuora

    For patients with rheumatoid arthritis (RA) that was active despite previous methotrexate therapy, the combination of tofacitinib plus methotrexate was as effective as adalimumab plus methotrexate in a head-to-head trial. However, tofacitinib monotherapy did not show non-inferiority to either combination therapy. “These results would suggest

    更新日期:2017-09-06
  • Surgery: Falling out of love with knee arthroscopy
    Nat. Rev. Rheumatol. (IF 12.188) Pub Date : 2017-07-06
    Teppo L. N. Järvinen, Gordon H. Guyatt

    Knee arthroscopy, the most common orthopaedic procedure, is used to treat middle-aged or elderly patients with knee pain, with over two million patients undergoing this surgery every year worldwide. A new clinical practice guideline advises against the use of arthroscopy in these patients, contradicting the common use of this procedure in clinical practice.

    更新日期:2017-09-06
  • Rheumatoid arthritis: Regulating the osteoclast workforce
    Nat. Rev. Rheumatol. (IF 12.188) Pub Date : 2017-08-03
    Jessica McHugh

    New findings published in Immunity shed light on the mechanisms by which hypoxia augments inflammation and bone destruction in pathologic inflammatory conditions such as rheumatoid arthritis. In this study, Murata et al. identify COMM domain-containing protein 1 (COMMD1) as both a negative

    更新日期:2017-09-06
  • Osteoarthritis: Time to put steroid injections behind us?
    Nat. Rev. Rheumatol. (IF 12.188) Pub Date : 2017-07-27
    Henning Bliddal, Marius Henriksen

    Intra-articular corticosteroid injections are a long-established treatment for knee osteoarthritis (OA), but new findings indicate they are not effective, and even potentially harmful. Is it time to rethink the use of this treatment?

    更新日期:2017-09-06
  • Vasculitis: Mepolizumab for eosinophilic granulomatosis with polyangiitis
    Nat. Rev. Rheumatol. (IF 12.188) Pub Date : 2017-08-03
    Loïc Guillevin

    Targeting IL-5 could improve outcomes and have steroid-sparing effects in the management of eosinophilic granulomatosis with polyangiitis. However, some questions remain about how this approach affects specific aspects of the disease.

    更新日期:2017-09-06
  • Regenerative medicine: Breaking Prometheus's curse for cartilage regeneration
    Nat. Rev. Rheumatol. (IF 12.188) Pub Date : 2017-07-27
    Florence Apparailly

    Like the mythical eagle devouring Prometheus's liver as fast as it regrew, chronic inflammation hinders cartilage regeneration in inflammatory arthritis. Using stem cells engineered to secrete anti-inflammatory molecules in response to local inflammatory factors could provide a way to keep the eagle at bay as the stem cells differentiate into chondrocytes.

    更新日期:2017-09-06
  • Regenerative medicine: Cartilage stem cells identified, but can they heal?
    Nat. Rev. Rheumatol. (IF 12.188) Pub Date : 2017-08-10
    Andrei S. Chagin, Ekaterina V. Medvedeva

    Regeneration of articular cartilage has been a long-standing challenge in the field of regenerative medicine. In the past 2 years, several studies have genetically identified the presence of stem cells in the surface of articular cartilage, but questions remain as to the healing properties of these cells.

    更新日期:2017-09-06
  • Pain management: Opioids for RA: a clinical dilemma
    Nat. Rev. Rheumatol. (IF 12.188) Pub Date : 2017-08-03
    Winfried Häuser, Mary-Ann Fitzcharles

    Opioids provide some modest pain relief for patients with rheumatoid arthritis, but prescription of these drugs is influenced by their association with risks for the individual and for society. Is denial of a treatment, even if that treatment is imperfect, justified when patients experience considerable pain and other treatment options are limited?

    更新日期:2017-09-06
  • Antigen-specific immunotherapies in rheumatic diseases
    Nat. Rev. Rheumatol. (IF 12.188) Pub Date : 2017-07-13
    Judit Pozsgay, Zoltán Szekanecz, Gabriella Sármay

    The main goal of antigen-specific immunotherapy (ASI) in autoimmune and rheumatic diseases is to reprogramme or remove autoreactive cells and/or induce immune tolerance to self-antigens. Current therapies in these diseases either treat symptoms or slow down disease progression but are not yet curative or preventative — disease-specific treatments are urgently needed. In contrast to the nonspecific treatments in current use that induce generalized immune suppression, which is associated with several adverse effects including increased risk of infections, ASIs target a restricted subset of B cells or T cells, and thus do not compromise systemic immunity and host defence. This Review provides a summary of novel approaches for identifying autoepitopes and detecting and targeting autoreactive cells that might help in the development of ASIs. Promising approaches include the use of tolerizing peptides coupled to MHC constructs and/or nanocompounds, tolerizing dendritic cells and antigen-specific vaccines. Following studies in animal models of rheumatoid arthritis and systemic lupus erythematosus, several of these strategies have now entered clinical trials. However, to use these approaches in humans, several important limitations must first be addressed, such as; selecting the proper immunodominant autoantigen; identifying the optimal timing, dosing and route of administration; finding biomarkers for monitoring the therapy; and optimizing methodology.

    更新日期:2017-09-06
  • The complement system as a potential therapeutic target in rheumatic disease
    Nat. Rev. Rheumatol. (IF 12.188) Pub Date : 2017-08-10
    Leendert A. Trouw, Matthew C. Pickering, Anna M. Blom

    Complement activation is associated with common rheumatic diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and systemic vasculitis. Evidence linking complement activation to these diseases includes the presence of complement deposition in affected tissues, decreased levels of complement proteins and high levels of complement activation fragments in the blood and/or synovial fluid of patients with these diseases, as well as data from experimental models. Eculizumab, a monoclonal antibody that inhibits the complement component C5, is now approved for the treatment of rare conditions involving complement hyperactivation, and the success of this therapy has renewed interest in understanding the utility of complement inhibition in rheumatological practice, particularly for SLE. For example, inhibiting C5 is a potential means of reducing glomerular inflammation in lupus nephritis or treating thrombotic microangiopathy in SLE. The complement system is one of multiple mediators of tissue injury in complex diseases such as SLE, and identifying the disease context in which complement activation has a predominant role is a challenge. An added difficulty in RA is identifying a role for therapeutic complement inhibition within the diverse treatment modalities already available. In this Review, evidence for the therapeutic potential of complement manipulation in rheumatology practice is evaluated.

    更新日期:2017-09-06
Some contents have been Reproduced with permission of the American Chemical Society.
Some contents have been Reproduced by permission of The Royal Society of Chemistry.
所有期刊列表A-Z